Abbvie Inc.'s chief scientific officer Michael Severino told BioWorld Today that "a dedicated group of scientists who really understood the biology and how to use the tools" worked for two decades to come up with Venclexta (venetoclax), which won accelerated approval by the FDA Monday for patients with chronic lymphocytic leukemia (CLL) who exhibit the 17p deletion.